Patheon provides unique access to the industry’s widest range of complex formulation technologies for small molecules and biologics.
Durham, NC (PRWEB) October 19, 2011
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Mark J. Kontny, Patheon’s President of Global Pharmaceutical Development Services and Chief Scientific Officer, and other senior scientific executives of the company, will be available to discuss the success it has generated from its industry leading expertise in developing complex formulation solutions for the pharmaceutical industry.
In commenting on Patheon’s complex formulation expertise, Dr. Kontny said, “Patheon provides unique access to the industry’s widest range of complex formulation technologies for small molecules and biologics. We’ve forged our expertise over thousands of customer projects by providing a choice of formulation technologies to solve complex development problems with the benefit of never paying a royalty. Whether our customers are developing a new product, or looking to sharpen their existing product’s competitive edge, they’ve found that our choice of technology options are the best available in the industry. It is what has put us in the number one market position in pharmaceutical development and formulation in the world.”
Patheon representatives will be available to discuss the company’s industry leading complex formulation capabilities at the upcoming AAPS Exposition in Washington, D.C. from October 24 through October 26, 2011. The company will be exhibiting at Booth 2201 through the duration of the conference. For those companies that are interested in discussing this program and will not be attending the conference, please contact a Patheon representative at 1-866-728-4366.
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. The company’s integrated development and manufacturing network of 10 facilities, nine development centers and one clinical trial packaging facility across North America and Europe, ensures that customer products can be launched with confidence anywhere in the world.